DUBLIN--(BUSINESS WIRE)--The "Bleeding Disorders Treatment - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
According to the report,The Global Bleeding Disorders Treatment Market accounted for $11.14 billion in 2017 and expected to grow at a CAGR of 8.4% to reach $23.04 billion by 2026.
Factors like growth in R&D investment for hemophilia products, inclination towards prophylactic treatment, increasing number of hemophilia patients, and the emergence of biosimilars products are fuelling the market growth.
Patent expiry of existing brands provide generic drug manufacturers an opportunity to enter, as well as sustaining healthcare infrastructure in developing economies with advancement in technology for development of new drugs and therapies will provide ample opportunity for the market growth.
The market will also witness emerging trends like high entry barriers created by local government and low switching rate for hemophilia products.
However, high cost of hemophilia drugs and inadequate reimbursement and lack of availability of skilled professionals are hampering the market growth.
North America is attributed to dominate the market during the forecast period owing to high acceptance for prophylaxis treatment among all age groups in the U.S. However, Asia Pacific is projected to grow at highest CAGR during the forecast period, due to increasing awareness of these disorders and availability of cheap generic drugs in the emerging economies such as India and China.
Key Topics Covered
1 Executive Summary
2 Preface
3 Market Trend Analysis
4 Porter's Five Forces Analysis
5 Global Bleeding Disorders Treatment Market, By Drug
6 Global Bleeding Disorders Treatment Market, By Type
7 Global Bleeding Disorders Treatment Market, By Therapy
8 Global Bleeding Disorders Treatment Market, By Geography
9 Key Developments
10 Company Profiling
- Alnylam Pharmaceuticals
- Amgen Inc.
- Baxalta (Now Shire)
- Bayer Pharmaceuticals
- Biogen Inc.
- Bristol-Myers Squibb Company
- Cangene Corporation
- CSL Behring
- Grifols S.A.
- Janssen Pharmaceuticals
- Novo Nordisk A/S
- Octapharma
- Pfizer Inc.
- Sanofi
- Xenetic Biosciences Inc.
For more information about this report visit https://www.researchandmarkets.com/research/rxnm5t/the_global?w=4
